Our study demonstrates that PLL-modified nHAp can effectively deliver MRPL21 siRNA to inhibit tumor growth in vivo, underscoring MRPL21 as a promising therapeutic target and chemosensitizer for head and neck cancer (Fig. 8). Here, MRPL21 is linked to neoplasm.